Phase 2Status unknownAge-related condition
Temsirolimus Adventitial Delivery to Improve Angiographic Outcomes Below the Knee (TANGO)
- Sponsor
- Mercator MedSystems, Inc. (Industry)
- Enrollment
- 100 planned
- Conditions
- Chronic Limb Ischemia
- Interventions
- Temsirolimus; Saline
- Ages
- adults, older adults
- Registry
- NCT02908035
Full record on ClinicalTrials.gov
From the registry
This is a prospective, multi-center, randomized, dose escalation study to document the effects of adventitial delivery of temsirolimus (Torisel) after revascularization of lesions below the knee in symptomatic patients with critical limb ischemia (CLI).
Primary outcomes
- Freedom from MALE-POD
- Transverse-view vessel area loss percentage (TVAL%) of the target lesion
History
Study completion
Primary completion
Last registry update
Started
Registered